Migraine Drug Succeeds in Study
While most migraine sufferers experience attacks once or twice a month, about 14 million people in the U.S. suffer headaches on a near-daily basis. All told, about 18% of American women and 6% of men suffer from migraine.
A drug that would prevent migraines would seem like a miracle to these folks.
Although not quite a miracle, there is encouraging news on that front. Alder BioPharmaceuticals Inc. announced that its drug to prevent migraines met the main goal in a mid-stage study, the results of which support a quarterly single injection dosing strategy.
Four doses of the drug, ALD403, were tested against a placebo in patients suffering from chronic migraines -- people who experienced 15 or more headache days per month -- with at least 8 assessed as migraine days.
The two highest doses of the drug, 300 mg and 100 mg, brought about a 75% reduction in migraine days in 33% and 31% of patients respectively, meeting the main goal of the study. The company further stated that a single infusion of 300mg, 100mg or 30mg doses resulted in a durable reduction in migraine days during a 12 week period, supporting a quarterly dosing strategy.
The side-effects of existing preventative medicines for migraine, including beta blockers and botox, limits their use. As a result, only about 12% of adults with frequent episodic or chronic migraine take preventive medication.